Schond Greenway

Schond Greenway

Geen lopende functies
54 jaar
Health Technology
Consumer Services
Finance

Profiel

Schond L.
Greenway
worked at Halozyme Therapeutics, Inc. as Executive Director-Strategy & IR from 2013 to 2016.
Worked at Mesoblast Ltd. as VP & Global Head-Investor Relations from 2016 to 2021.
Worked at Avalo Therapeutics, Inc. as Chief Financial Officer & Treasurer from 2021 to 2022.
Worked at Definium Therapeutics, Inc. as Chief Financial Officer from 2022 to 2024.
Also held positions at DURECT Corp.
as VP-Investor Relations & Strategic Planning and at Barclays Capital, Inc. as Vice President-Healthcare.
Education includes undergraduate studies at Florida A&M University and an MBA from the University of Virginia Darden School of Business.

Eerdere bekende functies van Schond Greenway

BedrijvenFunctieEinde
DEFINIUM THERAPEUTICS, INC. Financieel Directeur/CFO 03-05-2024
AVALO THERAPEUTICS, INC. Financieel Directeur/CFO 14-02-2022
MESOBLAST LIMITED Investor Relations Contact 01-02-2021
HALOZYME THERAPEUTICS, INC. Investor Relations Contact 01-01-2016
DURECT Public Communications Contact -
Ervaring van Schond Greenway in detail bekijken

Opleiding van Schond Greenway

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

54

Eerstegraads connecties

8

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit8

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Beurs
  2. Insiders
  3. Schond Greenway